Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.325
-0.015 (-1.12%)
Apr 29, 2026, 1:39 PM CET
-56.70%
Market Cap 40.73M
Revenue (ttm) 32.78M
Net Income (ttm) -28.48M
Shares Out 30.40M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,985
Average Volume 80,407
Open 1.350
Previous Close 1.340
Day's Range 1.300 - 1.350
52-Week Range 0.760 - 3.400
Beta 1.09
RSI 64.54
Earnings Date Apr 15, 2026

About STO:NEWBRY

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden. [Read more]

Sector Healthcare
Founded 2020
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol NEWBRY
Full Company Profile

Financial Performance

In fiscal year 2025, STO:NEWBRY's revenue was 31.57 million, a decrease of -14.27% compared to the previous year's 36.83 million. Losses were -23.88 million, 55.0% more than in 2024.

Financial Statements

News

There is no news available yet.